Evidence map›Paper›PMID 35976541›Full record

ArticleInvestigational new drugs2022

Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer.

Imene Ben Toumia, Marco Ponassi, Paola Barboro, Erika Iervasi, Gabriela Coronel Vargas, Barbara Banelli, Stefano Fiordoro, Leila Chekir Ghedira, Franz Heinrich Kohnke, Alberto Izzotti and 1 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Imene Ben ToumiaIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Marco PonassiIRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0002-5418-2458
Paola BarboroIRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0001-9074-9290
Erika IervasiIRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0002-7531-3373
Gabriela Coronel VargasIRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0002-7879-706X
Barbara BanelliIRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0003-1505-7141
Stefano FiordoroDIMES University of Genova, Genoa, Italy.
Leila Chekir GhediraUnit of Bioactive Natural Substances and Biotechnology UR17ES47, Faculty of Dental Medicine of Monastir, University of Monastir, Monastir, Tunisia.
Franz Heinrich KohnkeDepartment CHIBIOFARAM, University of Messina, Messina, Italy. franz@unime.it.
Alberto IzzottiIRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0002-8588-0347
Camillo RosanoIRCCS Ospedale Policlinico San Martino, Genoa, Italy. camillo.rosano@hsanmartino.it.ORCID 0000-0003-2949-9215
Ospedale Policlinico San Martino · ITUniversity of Genoa · ITUniversity of Messina · ITUniversity of Monastir · TN

Funding

European Cooperation in Science and Technology COST Action CA16231 - ENOVAEuropean Cooperation in Science and Technology COST Action CA 17104 - STRATAGEMMinistero della Salute 5x1000 2018-2019Ministero della Salute Ricerca Corrente 2021
6 · The paper itself

Abstract

Macrocyclic compounds meso-(p-acetamidophenyl)-calix[4]pyrrole and meso-(m-acetamidophenyl)-calix[4]pyrrole have previously been reported to exhibit cytotoxic properties towards lung cancer cells. Here, we report pre-clinical in vitro and in vivo studies showing that these calixpyrrole derivatives can inhibit cell growth in both PC3 and DU145 prostatic cancer cell lines. We explored the impact of these compounds on programmed cell death, as well as their ability to inhibit cellular invasion. In this study we have demonstrated the safety of these macrocyclic compounds by cytotoxicity tests on ex-vivo human peripheral blood mononuclear cells (PBMCs), and by in vivo subcutaneous administration. Preliminary in vivo tests demonstrated no hepato-, no nephro- and no genotoxicity in Balb/c mice compared to controls treated with cisplatin. These findings suggest these calixpyrroles might be novel therapeutic tools for the treatment of prostate cancer and of particular interest for the treatment of androgen-independent castration-resistant prostate cancer.

Indexed as

Antineoplastic AgentsPoriferaProstatic Neoplasms, Castration-ResistantAnimalsCell Line, TumorHumansLeukocytes, MononuclearMaleMiceMice, Inbred BALB CPyrrolesAntineoplastic AgentsPyrrolescalix[4]pyrrolesCancerChemoresistanceDrug developmentNew anticancer drugsProstate cancerTumour drug resistance

Identifiers

PMID35976541
OpenAlexW4292306523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.